The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing.
 
Jean-Francois Rossi
Consulting or Advisory Role - EUSA Pharma; Leo Pharma
Other Relationship - E-SANA Inc
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Corey Casper
Stock and Other Ownership Interests - Viracta Therapeutics
Consulting or Advisory Role - Curevo Vaccine; GlaxoSmithKline; Janssen; Temptime; Viracta Therapeutics
Speakers' Bureau - EUSA Pharma
Research Funding - Curevo Vaccine (Inst); iBio (Inst); ImmunityBio (Inst); Immunomic Therapeutics (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Publication royalties from UpToDate
Travel, Accommodations, Expenses - GlaxoSmithKline; Temptime
 
Peter M. Voorhees
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Janssen (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Sanofi
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Luis Fayad
Consulting or Advisory Role - EUSA Pharma; medicamenta ecuatoriana; Roche
 
Karan Kanhai
Employment - EUSA Pharma
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Advanced Therapeutics; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; Meyer Consulting; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Daiichi Sankyo; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoMed; Pfizer; Prosperdtx; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
 
Frits Van Rhee
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Janssen Biotech; Sanofi; Takeda